SUSANNA PITRUZZELLO: Open Payments
NPI 1811293087 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$856 in 39 payments from 22 companies in 2025. Trend: 2023 $911 · 2024 $859 · 2025 $856
Food & beverage: $773Education: $83
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $196 |
| Aveo Pharmaceuticals, Inc. | 1 | $83 |
| Exelixis Inc. | 3 | $57 |
| TerSera Therapeutics LLC | 2 | $54 |
| Immunocore Limited | 1 | $52 |
| Stemline Therapeutics Inc. | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Genmab U.S., Inc. | 2 | $37 |
| PFIZER INC. | 2 | $35 |
| BeOne Medicines USA, Inc. | 2 | $33 |
Products named: Fabhalta, FOTIVDA, CABOMETYX, Zoladex, KIMMTRAK, BRUKINSA, Orserdu, KISQALI.
Industry payments across AL — which companies pay providers there.
